Skip to Content

Genvoya vs Stribild for HIV - How do they compare?

Medically reviewed by Drugs.com. Last updated on Oct 7, 2019.

Official Answer

by Drugs.com

Genvoya and Stribild are both four-drug, antiviral combinations containing elvitegravir, cobicistat, emtricitabine, and tenofovir indicated as complete regimens for the treatment of HIV-1 infection. The difference between Genvoya and Stribild is in the form of tenofovir contained in each product. Genvoya contains a newer form of tenofovir called tenofovir alafenamide (TAF) and Stribild contains the original form of tenofovir as tenofovir disoproxil fumarate (TDF).

Tenofovir alafenamide is a prodrug of tenofovir that has been designed to enter HIV-infected cells more efficiently than TDF, and it can therefore be given at a much lower dose (less than one-tenth) than TDF. TAF appears to be associated with less kidney toxicity and decreases in bone density compared to TDF.

The dose for both Genvoya and Stribild is one tablet taken orally once daily with food.

Genvoya Stribild
FDA Approved November 5, 2015 August 27, 2012
How Supplied Each tablet contains:
  • elvitegravir 150 mg
  • cobicistat 150 mg
  • emtricitabine 200 mg
  • tenofovir alafenamide fumarate 10 mg
 Each tablet contains:
  • elvitegravir 150 mg
  • cobicistat 150 mg
  • emtricitabine 200 mg
  • tenofovir disoproxil fumarate 300 mg
Indication HIV-1 Infection
  • adults and pediatric patients weighing at least 25 kg
 HIV-1 Infection
  • adults and pediatric patients 12 years of age and older weighing at least 35 kg

Genvoya and Stribild are both manufactured by Gilead Sciences Inc.

Related Medical Questions

Related Support Groups

Medical Disclaimer